Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list

Jan 8, 2025 · Clarivate’s Drugs to Watch in 2025 report (PDF) predicts that Novo’s new once-weekly insulin Awiqli will pick up $4.7 billion in sales by 2030, making it one of the hottest launches of the year.

CouponFollow Extension

$4
OFF

Launches From Novo, Lilly Top Clarivate's Annual 'Drugs To Watch' List

3 weeks from now

fiercepharma.com

$1
OFF

Blockbusters In Waiting: Clarivate's Drugs To Watch In 2023

3 weeks from now

4 days ago · New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical …

pharmaphorum.com

FAQs about Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list Coupon?

What is the drugs to watch TM report?

Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch ™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. ...

Does Novo Nordisk have a drug to watch list?

The latest edition of the company's annual Drugs to Watch list zeroes in on drugs in late-stage development or recent launches with the potential to transform treatment on a global scale, with Novo Nordisk the only drugmaker to have more than one product that made the cut. ...

Will Clarivate predictive analytics be a blockbuster in 2024?

This year, analysts identified 13 new-to-market therapeutics and drugs poised to launch in 2024 which Clarivate predictive analytics project will achieve blockbuster status by 2029 or deliver game-changing benefits to patients. ...

Which il-23-targeting drugs are on the blockbuster list?

8) Mirikizumab: Eli Lilly's second candidate on the blockbuster list is a monoclonal antibody targeting the p19 subunit of IL-23, heading for a first-in-class approval in ulcerative colitis and third place for IL-23-targeting drugs in Crohn's disease after Johnson & Johnson's Stelara (ustekinumab) and AbbVie's Skyrizi (risankizumab); ...